\documentclass[11pt,twoside]{article}\makeatletter

\IfFileExists{xcolor.sty}%
  {\RequirePackage{xcolor}}%
  {\RequirePackage{color}}
\usepackage{colortbl}
\usepackage{wrapfig}
\usepackage{ifxetex}
\ifxetex
  \usepackage{fontspec}
  \usepackage{xunicode}
  \catcode`⃥=\active \def⃥{\textbackslash}
  \catcode`❴=\active \def❴{\{}
  \catcode`❵=\active \def❵{\}}
  \def\textJapanese{\fontspec{Noto Sans CJK JP}}
  \def\textChinese{\fontspec{Noto Sans CJK SC}}
  \def\textKorean{\fontspec{Noto Sans CJK KR}}
  \setmonofont{DejaVu Sans Mono}
  
\else
  \IfFileExists{utf8x.def}%
   {\usepackage[utf8x]{inputenc}
      \PrerenderUnicode{–}
    }%
   {\usepackage[utf8]{inputenc}}
  \usepackage[english]{babel}
  \usepackage[T1]{fontenc}
  \usepackage{float}
  \usepackage[]{ucs}
  \uc@dclc{8421}{default}{\textbackslash }
  \uc@dclc{10100}{default}{\{}
  \uc@dclc{10101}{default}{\}}
  \uc@dclc{8491}{default}{\AA{}}
  \uc@dclc{8239}{default}{\,}
  \uc@dclc{20154}{default}{ }
  \uc@dclc{10148}{default}{>}
  \def\textschwa{\rotatebox{-90}{e}}
  \def\textJapanese{}
  \def\textChinese{}
  \IfFileExists{tipa.sty}{\usepackage{tipa}}{}
\fi
\def\exampleFont{\ttfamily\small}
\DeclareTextSymbol{\textpi}{OML}{25}
\usepackage{relsize}
\RequirePackage{array}
\def\@testpach{\@chclass
 \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else
  \ifnum \@lastchclass=7 5 \else
   \ifnum \@lastchclass=8 \tw@ \else
    \ifnum \@lastchclass=9 \thr@@
   \else \z@
   \ifnum \@lastchclass = 10 \else
   \edef\@nextchar{\expandafter\string\@nextchar}%
   \@chnum
   \if \@nextchar c\z@ \else
    \if \@nextchar l\@ne \else
     \if \@nextchar r\tw@ \else
   \z@ \@chclass
   \if\@nextchar |\@ne \else
    \if \@nextchar !6 \else
     \if \@nextchar @7 \else
      \if \@nextchar (8 \else
       \if \@nextchar )9 \else
  10
  \@chnum
  \if \@nextchar m\thr@@\else
   \if \@nextchar p4 \else
    \if \@nextchar b5 \else
   \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi
   \fi \fi  \fi  \fi  \fi  \fi  \fi \fi \fi \fi \fi \fi}
\gdef\arraybackslash{\let\\=\@arraycr}
\def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}}
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\def\abbr{}
\def\corr{}
\def\expan{}
\def\gap{}
\def\orig{}
\def\reg{}
\def\ref{}
\def\sic{}
\def\persName{}\def\name{}
\def\placeName{}
\def\orgName{}
\def\textcal#1{{\fontspec{Lucida Calligraphy}#1}}
\def\textgothic#1{{\fontspec{Lucida Blackletter}#1}}
\def\textlarge#1{{\large #1}}
\def\textoverbar#1{\ensuremath{\overline{#1}}}
\def\textquoted#1{‘#1’}
\def\textsmall#1{{\small #1}}
\def\textsubscript#1{\@textsubscript{\selectfont#1}}
\def\textxi{\ensuremath{\xi}}
\def\titlem{\itshape}
\newenvironment{biblfree}{}{\ifvmode\par\fi }
\newenvironment{bibl}{}{}
\newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par }
\newenvironment{citbibl}{}{\ifvmode\par\fi }
\newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi }
\newenvironment{docDate}{}{\ifvmode\par\fi }
\newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi }
\newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par }
\newenvironment{msHead}{\vskip 6pt}{\par}
\newenvironment{msItem}{\vskip 6pt}{\par}
\newenvironment{rubric}{}{}
\newenvironment{titlePart}{}{\par }

\newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}}
\newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}}
\newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}}
\newcolumntype{P}[1]{){\arraybackslash}p{#1}}
\newcolumntype{B}[1]{){\arraybackslash}b{#1}}
\newcolumntype{M}[1]{){\arraybackslash}m{#1}}
\definecolor{label}{gray}{0.75}
\def\unusedattribute#1{\sout{\textcolor{label}{#1}}}
\DeclareRobustCommand*{\xref}{\hyper@normalise\xref@}
\def\xref@#1#2{\hyper@linkurl{#2}{#1}}
\begingroup
\catcode`\_=\active
\gdef_#1{\ensuremath{\sb{\mathrm{#1}}}}
\endgroup
\mathcode`\_=\string"8000
\catcode`\_=12\relax

\usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry}
\usepackage{framed}

\definecolor{shadecolor}{gray}{0.95}
\usepackage{longtable}
\usepackage[normalem]{ulem}
\usepackage{fancyvrb}
\usepackage{fancyhdr}
\usepackage{graphicx}
\usepackage{marginnote}

\renewcommand{\@cite}[1]{#1}


\renewcommand*{\marginfont}{\itshape\footnotesize}

\def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif}

  \pagestyle{fancy}

\usepackage[pdftitle={Diabetic Nephropathy: Causative and Protective Factors},
 pdfauthor={}]{hyperref}
\hyperbaseurl{}

	 \paperwidth210mm
	 \paperheight297mm
              
\def\@pnumwidth{1.55em}
\def\@tocrmarg {2.55em}
\def\@dotsep{4.5}
\setcounter{tocdepth}{3}
\clubpenalty=8000
\emergencystretch 3em
\hbadness=4000
\hyphenpenalty=400
\pretolerance=750
\tolerance=2000
\vbadness=4000
\widowpenalty=10000

\renewcommand\section{\@startsection {section}{1}{\z@}%
     {-1.75ex \@plus -0.5ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large\bfseries}}
\renewcommand\subsection{\@startsection{subsection}{2}{\z@}%
     {-1.75ex\@plus -0.5ex \@minus- .2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\Large}}
\renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}%
     {-1.5ex\@plus -0.35ex \@minus -.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\large}}
\renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}%
     {-1ex \@plus-0.35ex \@minus -0.2ex}%
     {0.5ex \@plus .2ex}%
     {\reset@font\normalsize}}
\renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}%
     {1.5ex \@plus1ex \@minus .2ex}%
     {-1em}%
     {\reset@font\normalsize\bfseries}}


\def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt}
 \@tempdima 1.5em \begingroup
 \parindent \z@ \rightskip \@pnumwidth 
 \parfillskip -\@pnumwidth 
 \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par
 \endgroup}
\def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}}
\def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}}
\def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}}
\def\l@subparagraph{\@dottedtocline{5}{10em}{5em}}
\@ifundefined{c@section}{\newcounter{section}}{}
\@ifundefined{c@chapter}{\newcounter{chapter}}{}
\newif\if@mainmatter 
\@mainmattertrue
\def\chaptername{Chapter}
\def\frontmatter{%
  \pagenumbering{roman}
  \def\thechapter{\@roman\c@chapter}
  \def\theHchapter{\roman{chapter}}
  \def\thesection{\@roman\c@section}
  \def\theHsection{\roman{section}}
  \def\@chapapp{}%
}
\def\mainmatter{%
  \cleardoublepage
  \def\thechapter{\@arabic\c@chapter}
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \pagenumbering{arabic}
  \setcounter{secnumdepth}{6}
  \def\@chapapp{\chaptername}%
  \def\theHchapter{\arabic{chapter}}
  \def\thesection{\@arabic\c@section}
  \def\theHsection{\arabic{section}}
}
\def\backmatter{%
  \cleardoublepage
  \setcounter{chapter}{0}
  \setcounter{section}{0}
  \setcounter{secnumdepth}{2}
  \def\@chapapp{\appendixname}%
  \def\thechapter{\@Alph\c@chapter}
  \def\theHchapter{\Alph{chapter}}
  \appendix
}
\newenvironment{bibitemlist}[1]{%
   \list{\@biblabel{\@arabic\c@enumiv}}%
       {\settowidth\labelwidth{\@biblabel{#1}}%
        \leftmargin\labelwidth
        \advance\leftmargin\labelsep
        \@openbib@code
        \usecounter{enumiv}%
        \let\p@enumiv\@empty
        \renewcommand\theenumiv{\@arabic\c@enumiv}%
	}%
  \sloppy
  \clubpenalty4000
  \@clubpenalty \clubpenalty
  \widowpenalty4000%
  \sfcode`\.\@m}%
  {\def\@noitemerr
    {\@latex@warning{Empty `bibitemlist' environment}}%
    \endlist}

\def\tableofcontents{\section*{\contentsname}\@starttoc{toc}}
\parskip0pt
\parindent1em
\def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}}
\newenvironment{reflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemsep}{0pt}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\itshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{sansreflist}{%
  \begin{raggedright}\begin{list}{}
  {%
   \setlength{\topsep}{0pt}%
   \setlength{\rightmargin}{0.25in}%
   \setlength{\itemindent}{0pt}%
   \setlength{\parskip}{0pt}%
   \setlength{\itemsep}{0pt}%
   \setlength{\parsep}{2pt}%
   \def\makelabel##1{\upshape ##1}}%
  }
  {\end{list}\end{raggedright}}
\newenvironment{specHead}[2]%
 {\vspace{20pt}\hrule\vspace{10pt}%
  \phantomsection\label{#1}\markright{#2}%

  \pdfbookmark[2]{#2}{#1}%
  \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}%
  }{}
      \def\TheFullDate{2015-05-15 (revised: 15 May 2015)}
\def\TheID{\makeatother }
\def\TheDate{2015-05-15}
\title{Diabetic Nephropathy: Causative and Protective Factors}
\author{}\makeatletter 
\makeatletter
\newcommand*{\cleartoleftpage}{%
  \clearpage
    \if@twoside
    \ifodd\c@page
      \hbox{}\newpage
      \if@twocolumn
        \hbox{}\newpage
      \fi
    \fi
  \fi
}
\makeatother
\makeatletter
\thispagestyle{empty}
\markright{\@title}\markboth{\@title}{\@author}
\renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@
\belowdisplayskip \abovedisplayskip
\abovedisplayshortskip \z@ plus2\p@
\belowdisplayshortskip 4\p@ plus2\p@ minus2\p@
\def\@listi{\leftmargin\leftmargini
               \topsep 2\p@ plus1\p@ minus1\p@
               \parsep 2\p@ plus\p@ minus\p@
               \itemsep 1pt}
}
\makeatother
\fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm}
\fancyhf{} 
\setlength{\headheight}{14pt}
\fancyhead[LE]{\bfseries\leftmark} 
\fancyhead[RO]{\bfseries\rightmark} 
\fancyfoot[RO]{}
\fancyfoot[CO]{\thepage}
\fancyfoot[LO]{\TheID}
\fancyfoot[LE]{}
\fancyfoot[CE]{\thepage}
\fancyfoot[RE]{\TheID}
\hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true}
\fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}}

\date{}
\usepackage{authblk}

\providecommand{\keywords}[1]
{
\footnotesize
  \textbf{\textit{Index terms---}} #1
}

\usepackage{graphicx,xcolor}
\definecolor{GJBlue}{HTML}{273B81}
\definecolor{GJLightBlue}{HTML}{0A9DD9}
\definecolor{GJMediumGrey}{HTML}{6D6E70}
\definecolor{GJLightGrey}{HTML}{929497} 

\renewenvironment{abstract}{%
   \setlength{\parindent}{0pt}\raggedright
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
   \textcolor{GJBlue}{\large\bfseries\abstractname\space}
}{%   
   \vskip8pt
   \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}}
   \vskip16pt
}

\usepackage[absolute,overlay]{textpos}

\makeatother 
      \usepackage{lineno}
      \linenumbers
      
\begin{document}

             \author[1]{Liang  Zhou}

             \author[2]{Guanjing  Zhang}

             \author[3]{Zhiyan  Xu}

             \author[4]{Khrystyna  Pronyuk}

             \author[5]{Xingming  Chen}

             \affil[1]{  E-Techco Information Technologies Co.Ltd}

\renewcommand\Authands{ and }

\date{\small \em Received: 7 April 2015 Accepted: 1 May 2015 Published: 15 May 2015}

\maketitle


\begin{abstract}
        


Diabetic nephropathy (DN) is the major cause of chronic kidney disease (CKD) which normally leads to end stage renal disease (ESRD) or dialysis. Despite vigorous management including treatment of hypertension, glyceamic control and the utilization of inhibitors of renin angiotensin system (RAS), a significant proportion of diabetic patients still develop CKD and progress to ESRD. Advances in understanding of the pathogenesis and pathology of DN have made it clear that DN occurs as a result of imbalance between causative factors and endogenous protective factors. To emphasize this concept, this review will focus on some of the current knowledge concerning both causative and endogenous protective factors of DN.

\end{abstract}


\keywords{diabetic nephropathy, causative factor, protective factor, protein kinase c, connective tissue growth factor, nuclear factor kappa b, osteopontin, rea}

\begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) 
\textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark}
\end{textblock*}

\begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) 
\textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}}
\end{textblock*}


\let\tabcellsep& 	 	 		 
\section[{Introduction}]{Introduction}\par
iabetic nephropathy (DN), a common and severe complication of Diabetes mellitus (DM), is the major cause of chronic kidney disease (CKD) which normally leads to end stage renal disease or dialysis. It is estimated that the number of people with diabetes will double by 2030 around the world, and the situation is more serious in developing country \hyperref[b0]{[1,}\hyperref[b1]{2]}. The mortality of dialysis patients with DN is higher than that of non-diabetic patient \hyperref[b2]{[3]}. Thus, the thorough understanding of pathophysiology of DN will be one of the most important medical concerns in the future.\par
Numerous efforts have been made to investigate the molecular mechanism of DN with an aim to identify causative factors. The data indicated that hemodynamic and metabolic factors contribute to the development of DN \hyperref[b4]{[4]}\hyperref[b5]{[5]}\hyperref[b8]{[6]}. Hemodynamic factors include alterations in flow and pressure, and the activation of renin-angiotensin system (RAS) \hyperref[b2]{[3]}. Hyperglycemia related pathways are also activated, which lead to the formation of advanced glycation end products (AGEs), over-expression of protein kinase C (PKC), increased oxidative stress \hyperref[b5]{[5,}\hyperref[b8]{6]}. Clinical strategies based on some of these causative factors for preventing DN, include inhibition of RAS via angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB); endothelin antagonists \hyperref[b9]{[7,}\hyperref[b10]{8]}. However, recent studies demonstrate that these clinical strategies only delay but cannot stop the progression of DN \hyperref[b11]{[9,}\hyperref[b12]{10]}.\par
Advances in understanding of the pathogenesis and pathology of DN have made it clear that DN occurs as a result of imbalance between causative factors and endogenous protective factors (Fig.  {\ref 1}). Both aspects of DN mechanisms provide potential targets for disease prevention. To emphasize this concept, this review will focus on some of the current knowledge concerning both causative factors and endogenous protective factors.  
\section[{Causative Factors}]{Causative Factors}\par
The most significant changes which characterize DN include glomerular and tubular hypertrophy, thickening of the peripheral glomerular basement membrane, mesangial expansion, glomerulosclerosis and tubulointerstitial fibrosis \hyperref[b13]{[11]}. These structural changes occurs as a result of an interaction between hemodynamic and metabolic factors, and finally lead to increased glomerular filtration rate (GFR), proteinuria, systemic hypertension and the loss of renal function \hyperref[b4]{(4,}\hyperref[b14]{12)}. Numerous efforts have been made to study the major causative molecules or pathways which include AGE, PKC, NF-?B, CTGF, ROS, Osteopontin (Fig. \hyperref[fig_2]{2}).  Advanced glycation end products (AGEs) as a result of chronic hyperglycemia and oxidative stress have been postulated to play major roles not only in the development of DN, but also in a range of cardiovascular complications \hyperref[b15]{[13,}\hyperref[b16]{14]}. It is reported that AGE exert toxicity via three mechanisms: deposition, in situ glycation and receptor interaction \hyperref[b8]{[6]}. Among these three mechanisms, the interactions between AGEs and their receptors (RAGE) play a major role in the progress of DM, especially DN. Its receptor is expressed on the surface of kidneys endothelial cells, podocytes, monocytes/macrophages, tubular and mesangial cells \hyperref[b17]{[15,}\hyperref[b18]{16]}. Binding of AGEs to the RAGE on these cell types will stimulate oxidative stress generation, activate intracellular molecules such as PKC, TGF -? , VEGF and NF-?B, evoke inflammatory and fibrogenic reactions, thereby causing progressive alteration in renal architecture and loss of renal function in DN \hyperref[b8]{[6,}\hyperref[b19]{17]}. The function of AGE-RAGE signaling pathway in the progress of DN has been proved by using the double transgenic mice mode which over expresses both iNOS and RAGE \hyperref[b21]{[18]}. In this study, transgenic mice developed glomerular lesions rapidly, which could be prevented by AGEs inhibitor \hyperref[b21]{[18]}.  {\ref Soulis et al. (1996)} initiated a research which also confirmed the beneficial effect of an AGE inhibitor Aminoguanidine in reducing the AGEs levels in blood and tissue of diabetic rats \hyperref[b23]{[19]}. Similar beneficial effect was observed by using alagebrium, a putative AGEs cross-link breaker, to treat DM rodent model \hyperref[b24]{[20]}. However, clinical trials for these AGE inhibitors were stopped due to toxicity of these inhibitors \hyperref[b25]{[21]}. Thus, these studies provide further evidence that AGEs is a promising therapy target for DN and efforts should be made to find new inhibitor of AGEs for treatment of DN. 
\section[{Volume XV Issue II Version}]{Volume XV Issue II Version} 
\section[{b) Protein Kinase c}]{b) Protein Kinase c}\par
Protein kinase C (PKC) belongs to the family of serine threonine kinase that act as an intracellular signal transduction system for many hormones and cytokines Diabetic Nephropathy: Causative and Protective Factors \hyperref[b26]{[22]}. PKC has 15 different isoforms, many of which have been indicated to be involved in diabetic complications \hyperref[b11]{[9]}. Among 15 isoforms of PKC, ?, ?, and ? isoforms have been most consistently implicated in DN. In DN, PKC isoforms, activated by enhanced diacylglycerol (DAG) and increased activity of polyol pathway, involves in numerous cellular pathways including NADH, ROS, Na+/K+ ATPase, Ang?, MAPK, VEGF, TGF-? and finally leads to series of physiological and structure changes such as endothelial dysfunction, glomerular basement membrane thickening, extracellular matrix accumulation, mesangial expansion, renal tubular fibrosis and glomerulosclerosis \hyperref[b11]{[9,}\hyperref[b12]{10,}\hyperref[b27]{23]}.\par
A range of novel compounds has been recently examined to inhibit PKC dependent pathways in DN. Ruboxistaurin, a selective inhibitor of the PKC-?, could normalize glomerular hyperfiltration, attenuate histological injury and functional decline, and reduce TGF-? levels and proteinuria \hyperref[b28]{[24]}. A randomized clinical study has been carried out, in which the patients with DN took ruboxistaurin orally for one year. The study showed that DN patients treated with ruboxistaurin daily had a 24\% greater decline in albuminuria than those given the placebo, and they had a stable estimated glomerular filtration rate as well \hyperref[b29]{[25]}. In a recent study conducted by \hyperref[b24]{Bhattacharya et al. (2013)}, it was found that the upregulation and activation of PKC isoforms ?, ?, and ? in the renal tissue of diabetes rats play a detrimental role in the pathogenesis of DN by accumulating of extracellular matrix through upregulation of TGF-?, fibronectin and type ? collagen \hyperref[b27]{[23]}. Treatment of diabetic rat with D-Saccharic acid 1, 4-lactone (DSL) could help to ameliorate alloxaninduced upregulation of PKC isoforms ?, ?, and ? as well as the accumulation of fibronectin and collagen \hyperref[b27]{[23]}. Thus, strategies to target PKC pathway using isoform-specific inhibitors could be one of the promising therapeutic options, but well-designed large and longterm clinical studies are needed to establish its efficacy for prevention and treatment of DN. 
\section[{c) Connective Tissue Growth Factor}]{c) Connective Tissue Growth Factor}\par
Connective tissue growth factor (CTGF), known as insulin-like growth factor-binding protein 8 (IGFBP8) and CCN2, is increasingly being implicated in structural and functional changes of diabetic renopathy \hyperref[b30]{[26]}. It is reported that the expression level of CTGF increased in glomerular and tubular of diabetes patients, and elevated in both early and late DN in humans \hyperref[b31]{[27]}. CTGF, stimulated by both hyperglycemia related factors, such as AGEs, and hemodynamic stimuli such as angiotensin \hyperref[b32]{[28,}\hyperref[b33]{29]}, is involved in mesangial cell hypertrophy, accumulation of extracellular matrix, epithelial-to-mesenchymal transition of tubular cells \hyperref[b31]{[27]}. CTGF is also a fibrogenic cytokine in the kidney and it is known to be a downstream mediator of the profibrotic effects of TGF-? inducing renal fibrosis \hyperref[b34]{[30,}\hyperref[b35]{31]}. In TGF-? mediated renal fibrosis, the activated type 1 receptor of TGF-? phosphorylates and activates members of the receptor-Smads (R-Smads; Samd2 and Smad 3) which then form oligomers with the co-Smad and regulate the expression of target genes in nucleus; Smad7, an inhibitory Smad, prevents the recruitment and phosphorylation of Smad2 and Smad3 \hyperref[b14]{[12]}. Several studies indicated that CTGF plays a central role in promoting the TGF-?/Smad signaling activity by decreasing the availability of smad7, which is inhibitory for Smad2 and 3 \hyperref[b31]{[27,}\hyperref[b36]{32]}. In an animal model of unilateral ureteral obstruction (UUO), it was found that CTGF antisense treatment could attenuate tubulointerstitial fibrosis which further confirms the role of CTGF on TGF-? inducing renal fibrosis \hyperref[b37]{[33]}. In a study conducted by Adler et al (2010), it was found that FG-3019, a humanized anti-CTGF monoclonal antibody, could decrease albuminuria of diabetic patients with incipient nephropathy effectively \hyperref[b38]{[34]}. These studies demonstrate that strategies specifically targeting CTGF to retard the development of renal disease are likely to be an excellent therapeutic strategy for DN, although prospective studies are lacking. 
\section[{d) Nuclear Factor Kappa b}]{d) Nuclear Factor Kappa b}\par
Nuclear factor Kappa B (NF-?B), a transcription factor, plays an important role in cell survival and its inhibition leads to apoptosis. In the latent state, NF-?B is sequestered in the cytosol by its inhibitor I?B \hyperref[b39]{[35]}. Upon stimulations, its inhibitor I?B will be phosphorylated and degraded rapidly. Proteasomal degradation of I?B ultimately frees NF-?B which then translocates into nuclear and activates targeted gene \hyperref[b39]{[35]}. Numerous studies indicated that NF-?B is important modulator of diabetic complications, especially in DN \hyperref[b40]{[36,}\hyperref[b41]{37]}. It is reported that NF-?B could be activated by a range of stimuli including high glucose, AGEs and ROS \hyperref[b42]{[38]}. And activated NF-?B in turn regulates numerous genes including cytokines, adhesion molecules, NO synthase, angiotensinogen and other inflammatory factor implicated in the process of DN \hyperref[b43]{[39]}. In addition, recent studies have indicated that NF-?B plays a key role in podocyte apoptosis \hyperref[b44]{[40]}, modulates the TGF-? intracellular signaling pathways \hyperref[b45]{[41]}, which provide further evidence for the role of NF-?B in the pathogenesis of DN. In a study conducted by \hyperref[b43]{Chiu et al. (2009)}, the typical characteristics of DN including mesangial expansion, accumulation of extracellular matrix were observed in rats injected with streptozotocin \hyperref[b46]{[42]}. After treating these diabetic rats with curcumin, an inhibitor of NF-?B, these diabetes-associated abnormalities were ameliorated. Similar beneficial effects were observed by using Polydatin and Lycopene, the putative inhibitors of NF-?B signal pathway, to treat DN rats induced by streptozotocin \hyperref[b47]{[43,}\hyperref[b48]{44]}. However, approaches to inhibit NF-?B have not been explored fully in clinical studies, most likely due to the intimate  
\section[{e) Osteopontin}]{e) Osteopontin}\par
Osteopontin (OPN), also known as secreted phosphoprotein 1, is a complex secreted glycoprotein that facilitates cell adhesion and migration by binding integrins with its RGD domain \hyperref[b49]{[45]}. OPN has also been shown to play a prominent role in inflammation via promoting macrophage retention and activating macrophage \hyperref[b50]{[46]}. Its role in DN has recently been examined in OPN gene knockout mice \hyperref[b51]{[47]}. It was found that diabetic OPN null mice have decreased albuminuria, glomerular extracellular matrix, mesangial area and TGF-? compared with their respective diabetic OPN+/+ littermates \hyperref[b51]{[47]}, which indicates that OPN promotes diabetic renal injury in diabetic OPN+/+ mice. Besides, the upregulated expression of OPN in human and mice with diabetes has been observed \hyperref[b52]{[48,}\hyperref[b53]{49]}. And OPN, induced by hyperglycemia and lipopolysaccharides \hyperref[b53]{[49]}, is expressed in all glomerular cells including mesangial cells, podocytes, and endothelial cells \hyperref[b54]{[50,}\hyperref[b55]{51]}. These results suggest that OPN contributes to DN via damage the glomerular cells. \hyperref[b50]{Lorenzen et al. (2008)} carried out an experiment to investigate the molecular mechanism of OPN on cultured podocytes \hyperref[b53]{[49]}. They found that OPN could activate NF-?B pathway, increase the expression of urokinase plasminogen activator and matrix metalloprotease, and finally lead to increased podocyte motility. The similar study was conducted by \hyperref[b48]{Nicholas et al. (2010)} in which the effect of OPN on cultured mouse mesangial cells was studied \hyperref[b51]{[47]}. The result shows that OPN could promote the accumulation of glomerular extracellular matrix through upregulating TGF-?, ERK/MAPK and JNK/MAPK signaling. They also found that the expression of TGF-? induced by glucose was inhibited by OPN antibodies. Thus, OPN seems to be a critical contributor to the pathogenesis of DN. However, further studies will be needed to validate whether OPN is truly a causative factor for DN or not. 
\section[{f) Reactive Oxygen Species}]{f) Reactive Oxygen Species}\par
High reactive oxygen species (ROS), induced by hyperglycemia, plays a prominent role in the pathogenesis of diabetic complications, especially DN \hyperref[b56]{[52,}\hyperref[b57]{53]}. It is reported that ROS could be produced by various types of cells which include endothelial cells, mesangial cells, podocytes, tubular epithelial cells under hyperglycemic \hyperref[b0]{[1,}\hyperref[b58]{54]}. Produced ROS are capable of disturb physiological function of these cells both directly, by oxidizing and damaging cellular macromolecules such as DNA, protein lipid and carbohydrate, and indirectly through the stimulation of multiple pathways, such as PKC, polyol pathways, NF-?B, RAAS, and accumulation of AGEs \hyperref[b56]{[52,}\hyperref[b59]{55]}. \hyperref[b53]{Zhang et al. (2012)} investigated the role of NADPH oxidase-derived ROS in cultured mesangial cell and found that high glucose could upregulate NADPH oxidase through JNK/NF-?B pathway and consequently produce ROS which finally contributes to glomerular mesangial cell proliferation and fibronectin expression \hyperref[b56]{[52]}. They also use resveratrol, a polyphenolic phytoalexin, to treat high glucose induced mesangial cell and the results showed that resveratrol could inhibit mesangial cell expansion and fibronectin expression through blocking JNK/NF-?B/NADPH oxidase/ROS signaling pathways \hyperref[b56]{[52]}. In another study, schizandrin, a blocker of NADPH oxidizeinduced ROS signaling, was utilized to treat murine mesangial cell cultured in high glucose media \hyperref[b60]{[56]}. The result showed that schizandrin inhibits high glucose induced mesangial cell proliferation and ECM overexpression through attenuating ROS level. Furthermore, a large number of experimental studies have proved the beneficial effect of antioxidants, such as Vitamins C and E, superoxide dismutase, and catalase, in ameliorating DN \hyperref[b61]{[57]}. However, it is also reported that ROS are involved in the regulation of renal hemodynamic and renal ion transport which is the key for maintaining basic function of kidney \hyperref[b62]{[58,}\hyperref[b63]{59]}. Therapeutic effect of ROS in preventing of DN is still debatable at this time. 
\section[{III.}]{III.} 
\section[{Endogenous Protective Factors}]{Endogenous Protective Factors}\par
The role of endogenous protective factors in the development of DN has been investigated widely. In a clinical research conducted by \hyperref[b61]{Perkins et al. (2003)}, 368 type 1 diabetic patien ts with microalbuminuria were followed up for 12 years \hyperref[b64]{[60]}. It was found that, among these diabetic patients, more than 60\% of type 1 diabetic patients were free from significant diabetic complications which suggest the presence of endogenous protective factors. Meanwhile, these results indicate that endogenous protective factors protect the diabetic patients from the progression of DN via neutralizing effect of risk factors such as PKC, ROS, TGF -? etc. 
\section[{a) Netrin-1}]{a) Netrin-1}\par
The netrin-1, a diffusible laminin-related secreted protein, is originally identified as a neuronal guidance cue which directs neurons and their axons to targets during the development of the nervous system \hyperref[b66]{[61]}. Recent investigations indicate that netrin-1 is highly expressed in many tissues outside the nervous system, especially in vascular endothelial cells of kidney to attenuate inflammation \hyperref[b67]{[62]}. An investigation conducted by Wang et al.  {\ref (2008)} showed that downregulation of netrin-1 correspond with the increased expression of MCP-1 and IL-6 and infiltration of leukocytes into the kidney \hyperref[b68]{[63]}. Mice with partial netrin-1 deficiency experience more severe degree of ischemic kidney injury because of exacerbated inflammation \hyperref[b69]{[64]}. Meanwhile, it is also reported that administration of recombinant netrin-1 in kidney could suppress inflammation and apoptosis in vivo \hyperref[b70]{[65]}.\par
DN is a manifestation of an ongoing chronic low-grade inflammation \hyperref[b72]{[66]}. The role of netrin-1 in DN has been investigated recently and the result showed that over-expression of netrin-1 could protect transgenic mice during DN via attenuating inflammation \hyperref[b73]{[67]}. In a study conducted by \hyperref[b69]{Tak et al. (2013)}, partial netrin-1 deficiency mice mode (Ntrn 1+/-) was introduced to investigate the role of netrin-1 protein in STZ induced diabetic mice \hyperref[b74]{[68]}. The result showed that Ntrn 1+/mice revealed a more severe degree of DN compared with wild-type mice \hyperref[b74]{[68]}. In addition, they found that treatment of DN with netrin-1 was associated with attenuated albuminuria and improved histological scores for DN. However, as most of these studies were done in animal model, further studies in clinic would be important to investigate its therapeutic function. 
\section[{b) Adiponectin}]{b) Adiponectin}\par
Adiponectin, known as ACRP30 and GBP28, is an adipokine produced by white adipocytes and encoded by the APM1 gene in humans and rodents \hyperref[b75]{[69]}. It has two receptors, AD1POR1 and ADIPOR2 which have been found to be widely expressed in liver, kidney, and endothelial cells \hyperref[b76]{[70]}. Through interacting with its receptors AD1POR1 and ADIPOR2, adiponectin could mediate increased 5'adenosine monophosphateactivated protein kinase (AMPK) and activate peroxisome proliferator-activated receptor alpha (PPAR?), respectively \hyperref[b76]{[70]}. Recently investigation indicated that adiponectin have insulin-sensitizing effects which include stimulation of fatty acid oxidation and glucose uptake in skeletal muscle and suppression of glucose production in the liver via activating of AMPK in the peripheral tissue \hyperref[b78]{[71,}\hyperref[b79]{72]}. They found that administration of adiponectin could lower circulating glucose levels without stimulating insulin secretion in both healthy and diabetic mice \hyperref[b79]{[72]}.\par
Besides, it is reported that adiponectin has a renoprotective effect in chronic renal disease including DN \hyperref[b80]{[73,}\hyperref[b81]{74]}. In an experiment conducted by Ohahsi et al.  {\ref (2007)}, the result showed that urine albumin excretion, glomerular hypertrophy and tubulointerstitial fibrosis were significantly worse in adiponectin knockout mice compared to wild type after performing subtotal (5/6) nephrectomy \hyperref[b81]{[74]}. Further study demonstrated that adiponectin knockout mice developed podocyte foot process effacement which is a key process involved in the initial development of albuminuria \hyperref[b82]{[75]}. \hyperref[b78]{Sharma et al. (2008)} also reported that administration of adiponectin to knockout mice could help normalize albuminuria and restore podocytes foot process effacement via activating of AMPK in podocytes \hyperref[b82]{[75]}.\par
These finding strongly supports the importance of adiponectin as a renoprotective factor. However, it is still unclear whether adiponectin will provide significant effects toward human DN. 
\section[{c) Activated Protein c}]{c) Activated Protein c}\par
Protein C, known as an anticoagulant factor, is activated by binding of thrombin to its receptor, thrombomodulin. After activation, it is reported that protein C confers cytoprotective effect in various disease models, including DN \hyperref[b83]{[76,}\hyperref[b85]{78]}. In diabetic patients and diabetic mice model, the function of endothelial thrombomodulin protein C system, which is in charge of activating protein C, is impaired and the level of activated protein C is reduced correspondingly \hyperref[b83]{[76,}\hyperref[b84]{77]}. The study conducted by \hyperref[b79]{Isermann et al., (2007)} also reported that the reduction of activated protein C in diabetic mice is responsible for the initiation of DN and maintaining high activated protein C level could protect glomerular filtration barrier by preventing glucoseinduced apoptosis in endothelial cells and podocytes \hyperref[b83]{[76]}. Besides, it is also reported that activated protein C have anti-inflammatory and fibrinolytic effects \hyperref[b86]{[79,}\hyperref[b87]{80]}. In unilaterally nephrectomized C57/B16 diabetic mice model, the urine total protein to creatinine ratio, proteinurine and renal fibrosis were ameliorated by administration of exogenous activated protein C \hyperref[b87]{[80]}. They also indicated that the concentration of causative factors such as monocyte chemoattractant protein-1 (MCP-1), TGF-?1 and CTGF were decreased significantly in APC-treated mice compared with untreated mice \hyperref[b87]{[80]}. Thus, APC appears to be a protective factor with anti-apoptosis, anti-inflammatory and fibrinolytic effects for DN and clinical studies are needed to validate its therapeutic role. 
\section[{d) Insulin}]{d) Insulin}\par
Insulin is an important vasotropic factor which regulates the function of vascular cells, such as endothelial cells, macrophages, and podocytes, via binding to its receptors on these cells \hyperref[b12]{[10]}. After binding to its receptors, insulin can activate the pathway of insulin receptor substrate (IRS)/PI3K/Akt/endothelial NO synthase (eNOS) and stimulate the production of NO which results in vasodilatation and anti-thrombosis in the short term, and can inhibit smooth muscle cell growth and migration chronically \hyperref[b88]{[81,}\hyperref[b89]{82]}. It is also reported that insulin could increases the expression of VEGF in several cell types, which in turn act as survival factor of podocytes, endothelial cells, and mesangial cells \hyperref[b90]{[83]}. Furthermore, the studies indicated that insulin could prevent apoptosis through inhibition of transcription factor FoxO \hyperref[b91]{[84]}  developed albuminuria, effacement of podocytes foot processes, increased deposition of components of the basal membrane, and a higher frequency of programmed podocytes apoptosis compared to control animals  {\ref [88]}. The pathology was quite similar to that seen in DN. Thus, this finding strongly supports the importance of insulin signaling as a renoprotective factor and improving insulin sensitivity in glomerular tissue may decrease the risk for DN.  
\section[{IV. Conclusions}]{IV. Conclusions}\begin{figure}[htbp]
\noindent\textbf{}\includegraphics[]{image-2.png}
\caption{\label{fig_0}Figure1:}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{2}\includegraphics[]{image-3.png}
\caption{\label{fig_2}Figure 2 :}\end{figure}
 \begin{figure}[htbp]
\noindent\textbf{}\includegraphics[]{image-4.png}
\caption{\label{fig_4}F}\end{figure}
   			\footnote{© 2015 Global Journals Inc. (US)} 		 		\backmatter   			 
\subsection[{Acknowledgements}]{Acknowledgements}\par
This work was supported by the grant from Shenzhen 2013 Overseas High Level Talents "Peacock" project (20130409 173324816). 			  			  				\begin{bibitemlist}{1}
\bibitem[Dash et al.]{b6}\label{b6} 	 		\textit{},  		 			A Dash 		,  		 			R Maiti 		,  		 			T K A Bandakkanavar 		,  		 			B L Pandey 		.  		 		 			Novel Drug Treatment for Diabetic Nephropathy 		 	 
\bibitem[Soulis et al.]{b19}\label{b19} 	 		\textit{},  		 			T Soulis 		,  		 			M E Cooper 		,  		 			D Vranes 		,  		 			R Bucala 		,  		 			G Jerums 		.  		 	 	 (Effects of aminoguanidine in preventing) 
\bibitem[ Arteriosclerosis, Thrombosis, and Vascular Biology ()]{b77}\label{b77} 	 		\textit{},  	 	 		\textit{Arteriosclerosis, Thrombosis, and Vascular Biology}  		2007. 27  (9)  p. .  	 
\bibitem[Kong ()]{b7}\label{b7} 	 		\textit{},  		 			Hong Kong 		.  	 	 		\textit{J Nephrol}  		2011. 13  (1)  p. .  	 
\bibitem[Bock et al. ()]{b81}\label{b81} 	 		‘Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66shc’.  		 			F Bock 		,  		 			K Shahzad 		,  		 			H J Wang 		,  		 			S Stoyanov 		,  		 			J Wolter 		,  		 			W Dong 		.  	 	 		\textit{PNAS}  		2013. 110  (2)  p. .  	 
\bibitem[Gilbert and Marsden ()]{b82}\label{b82} 	 		‘Activated protein C and diabetic nephropathy’.  		 			R E Gilbert 		,  		 			P A Marsden 		.  	 	 		\textit{N ENGL J MED}  		2008. 358  (15)  p. .  	 
\bibitem[Isermann et al. ()]{b79}\label{b79} 	 		‘Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocytes apoptosis’.  		 			B Isermann 		,  		 			I A Vinnikov 		,  		 			T Madhusudhan 		,  		 			S Herzog 		,  		 			M Kashif 		.  	 	 		\textit{Nat Med}  		2007. 13  (11)  p. .  	 
\bibitem[Geraldes and King ()]{b89}\label{b89} 	 		‘Activation of protein kinase C isoforms and its impact on diabetic complications’.  		 			P \& Geraldes 		,  		 			G L King 		.  	 	 		\textit{Circ. Res}  		2010. 106 p. .  	 
\bibitem[Naruse et al. ()]{b84}\label{b84} 	 		‘Activation of vascular protein kinase C-beta inhibits Akt-dependent endothelial nitrix oxide synthase function in obesity-associated insulin resistance’.  		 			K Naruse 		,  		 			C Rask-Madsen 		,  		 			N Takahara 		,  		 			S W Ha 		,  		 			K Suzuma 		.  	 	 		\textit{Diabetes}  		2006. 55 p. .  	 
\bibitem[Kadowaki and Yamauchi ()]{b73}\label{b73} 	 		‘Adiponectin and adiponectin receptors’.  		 			T Kadowaki 		,  		 			\& T Yamauchi 		.  	 	 		\textit{Endocrine Reviews}  		2005. 26  (3)  p. .  	 
\bibitem[Sweiss and Sharma ()]{b72}\label{b72} 	 		‘Adiponectin effects on the kidney’.  		 			N Sweiss 		,  		 			\& K Sharma 		.  	 	 		\textit{Best Practice \& Research Clinical Endocrinology \& Metabolism}  		2013. p. .  	 
\bibitem[Sharma et al. ()]{b78}\label{b78} 	 		‘Adiponectin regulates albuminuria and podocytes function in mice’.  		 			K Sharma 		,  		 			S Ramachandrarao 		,  		 			G Qiu 		.  	 	 		\textit{The journal of Clinical Investigation}  		2008. 118  (5)  p. .  	 
\bibitem[Nakamaki et al. ()]{b75}\label{b75} 	 		‘Adiponectinreduces proteinuria in streptozotocin-induced diabetic Wistar rats’.  		 			S Nakamaki 		,  		 			H Satoh 		,  		 			A Kudoh 		,  		 			Y Hayashi 		,  		 			H Hirai 		,  		 			T Watanabe 		.  	 	 		\textit{Exp. Biol. Med}  		2011. 236  (5)  p. .  	 
\bibitem[Nowotny and Hohn ()]{b14}\label{b14} 	 		‘Advanced glycation end products and oxidative stress in Type 2 Diabetes Mellitus’.  		 			K Nowotny 		,  		 			T 		,  		 			Jung Hohn 		.  	 	 		\textit{Biomolecules}  		2015. 5 p. .  	 
\bibitem[Chabroux et al. ()]{b13}\label{b13} 	 		‘Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but now retinopathy’.  		 			S Chabroux 		,  		 			F Canoui-Poitrine 		,  		 			S Reffet 		,  		 			G Mills-Joncour 		,  		 			E Mordlon 		,  		 			C Colin 		,  		 			C Thivolet 		.  	 	 		\textit{Diabetes \& Metabolism}  		2010. 36 p. .  	 
\bibitem[Daroux et al. ()]{b5}\label{b5} 	 		‘Advanced glycation end-products: iImplications for Diabetic and non-diabetic nephropathies’.  		 			M Daroux 		,  		 			G Prevost 		,  		 			H Maillard-Lefebvre 		,  		 			C Gaxatte 		,  		 			V D D'agati 		,  		 			A M Schmidt 		,  		 			E Boulanger 		.  	 	 		\textit{Diabetes \& Metabolism}  		2010. 36 p. .  	 
\bibitem[Twigg et al. ()]{b29}\label{b29} 	 		‘Advanced glycosylation end products up-regulate connective tissue growth factor (Insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: A potential mechanism for expansion of extracellular matrix in diabetes mellitus’.  		 			S M Twigg 		,  		 			M M Chen 		,  		 			A H Joly 		,  		 			S D Chakrapani 		,  		 			J Tsubaki 		,  		 			H S Kim 		,  		 			Y Oh 		,  		 			R G Rosenfeld 		.  	 	 		\textit{Endocrinology}  		2001. 142 p. .  	 
\bibitem[Yamagishi et al. ()]{b17}\label{b17} 	 		‘Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications’.  		 			S Yamagishi 		,  		 			K Nakamura 		,  		 			T Matsui 		,  		 			S Ueda 		,  		 			K Fukami 		,  		 			S Okuda 		.  	 	 		\textit{Expert Opin Invest Drugs}  		2008. 17 p. .  	 
\bibitem[Endlich et al. ()]{b51}\label{b51} 	 		‘Analysis of differential gene expression in stretched podocytes: osteopontin enhances adaptation of podocytes to mechanical stress’.  		 			N Endlich 		,  		 			M Sunohara 		,  		 			W Nietfeld 		,  		 			E W Wolski 		,  		 			D Schiwek 		,  		 			B Kränzlin 		,  		 			N Gretz 		,  		 			W Kriz 		,  		 			H Eickhoff 		,  		 			K Endlich 		.  	 	 		\textit{FASEB J}  		2002. 16 p. .  	 
\bibitem[Finckenberg et al. ()]{b30}\label{b30} 	 		‘Angiotensin ? induces connective tissue growth factor gene expression via calcineurin-dependent pathways’.  		 			P Finckenberg 		,  		 			K Inkinen 		,  		 			J Ahonen 		,  		 			S Merasto 		,  		 			M Louhelainen 		,  		 			H Vapaatalo 		,  		 			D Müller 		,  		 			D Ganten 		,  		 			F Luft 		,  		 			E Mervaala 		.  	 	 		\textit{American Journal of Pathology}  		2003. 163 p. .  	 
\bibitem[Guo et al. ()]{b45}\label{b45} 	 		‘Beneficial effect of lycopene on anti-diabetic nephropathy through diminishing inflammatory response and oxidative stress’.  		 			Y Guo 		,  		 			Y Liu 		,  		 			Wang 		.  	 	 		\textit{Food Funct}  		2015.  	 
\bibitem[Brezniceanu et al. ()]{b55}\label{b55} 	 		‘Catalase overexpression attenuates angiotensinogen expression and apoptosis in diabetic mice’.  		 			M L Brezniceanu 		,  		 			F Liu 		,  		 			C C Wei 		,  		 			S Tran 		,  		 			S Sachetelli 		,  		 			S L Zhang 		,  		 			D F Guo 		,  		 			J G Filep 		,  		 			J R Ingelfinger 		,  		 			J S Chan 		.  	 	 		\textit{Kidney Int}  		2007. 71 p. .  	 
\bibitem[Mesallamy et al. ()]{b31}\label{b31} 	 		‘Clinical significance of inflammatory and fibrogenic cytokines in diabetic nephropathy’.  		 			H O E Mesallamy 		,  		 			H H Ahmed 		,  		 			A A Bassyouni 		,  		 			A S Ahmed 		.  	 	 		\textit{Clinical Biochemistry}  		2012. 45 p. .  	 
\bibitem[Lr James et al. ()]{b32}\label{b32} 	 		‘Connective tissue growth factor (CTGF) expression modulates response to high glucose’.  		 			Lr James 		,  		 			H Le 		,  		 			Doherty 		.  	 	 		\textit{Plos One}  		2013. 8  (8) .  	 
\bibitem[Wahab et al. ()]{b33}\label{b33} 	 		‘Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor Trk A’.  		 			N A Wahab 		,  		 			B S Weston 		,  		 			R M Mason 		.  	 	 		\textit{J. Am. Soc. Nephrol}  		2005. 16 p. .  	 
\bibitem[Nicholas et al. ()]{b48}\label{b48} 	 		‘Critical role for osteopontin in diabetic nephropathy’.  		 			S B Nicholas 		,  		 			J Liu 		,  		 			J Kim 		,  		 			Y Ren 		,  		 			A R Collins 		,  		 			L Nguyen 		,  		 			W A Hsueh 		.  	 	 		\textit{Kidney International}  		2010. 77 p. .  	 
\bibitem[Chiu et al. ()]{b43}\label{b43} 	 		‘Curcumin prevents diabetes-associated abnormalities in the kidneys by inhibiting p300 and nuclear factor-?B’.  		 			J Chiu 		,  		 			H Farhangkhoee 		,  		 			S Chakrabarti 		.  	 	 		\textit{Nutrition}  		2009. 25 p. .  	 
\bibitem[Bhattacharya et al. ()]{b24}\label{b24} 	 		‘D-Saccharic acid 1, 4-lactone protects diabetic rat kidney by ameliorating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via NF-?B and PKC signaling’.  		 			S Bhattacharya 		,  		 			P Manna 		,  		 			R Gachhui 		,  		 			P C Sil 		.  	 	 		\textit{Toxicology and Applied Pharmacology}  		2013. 267 p. .  	 
\bibitem[Li et al. ()]{b80}\label{b80} 	 		‘Decreased activated protein C levels are inversely associated with the urinary albumin excretion rate in patients with type 2 diabetes’.  		 			W Li 		,  		 			Lin 		,  		 			He 		.  	 	 		\textit{Clin. Lab}  		2014. 60  (2)  p. .  	 
\bibitem[Chou et al. ()]{b86}\label{b86} 	 		‘Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue’.  		 			E Chou 		,  		 			L Suzuma 		,  		 			K J Way 		,  		 			D Opland 		,  		 			A C Clermont 		.  	 	 		\textit{Circulation}  		2002. 105 p. .  	 
\bibitem[Yamamoto et al. ()]{b18}\label{b18} 	 		‘Development and prevention of advanced diabetic nephropathy in RAGE overexpressing mice’.  		 			Y Yamamoto 		,  		 			I Kato 		,  		 			T Doi 		,  		 			H Yonekura 		,  		 			S Ohashi 		.  	 	 		\textit{J Clin Invest}  		2001. 108 p. .  	 
\bibitem[Diabetic Nephropathy: Causative and Protective Factors experimental diabetic nephropathy are related to the duration of treatment Kidney Int ()]{b20}\label{b20} 	 		‘Diabetic Nephropathy: Causative and Protective Factors experimental diabetic nephropathy are related to the duration of treatment’.  	 	 		\textit{Kidney Int}  		1996. 50 p. .  	 
\bibitem[Diabetic Nephropathy: Causative and Protective Factors mammalian target of rapamycin-mediated survival pathway by adenosine 5-Monophosphate-activated protein kinase Horm Metab Res ()]{b71}\label{b71} 	 		‘Diabetic Nephropathy: Causative and Protective Factors mammalian target of rapamycin-mediated survival pathway by adenosine 5-Monophosphate-activated protein kinase’.  	 	 		\textit{Horm Metab Res}  		2012. 44 p. .  	 
\bibitem[Soldatos and Cooper ()]{b4}\label{b4} 	 		‘Diabetic nephropathy: important pathophysiologic mechanisms’.  		 			G Soldatos 		,  		 			M E Cooper 		.  	 	 		\textit{Diabetes Research And Clinical Practice}  		2008. 82 p. .  	 
\bibitem[Gilbert et al. ()]{b25}\label{b25} 	 		\textit{Effect of ruboxistaurin on urinary transforming growth factor-beta in patients with diabetic nephropathy and type 2 diabetes. Diabetes Care},  		 			R E Gilbert 		,  		 			S A Kim 		,  		 			K R Tuttle 		,  		 			G L Bakris 		,  		 			R D Toto 		,  		 			J B Mcgill 		.  		2007. 30 p. .  	 
\bibitem[Liu et al. ()]{b38}\label{b38} 	 		‘Effects of berberine on matrix accumulation and NF-kappa B signal pathway in alloxan-induced diabetic mice with renal injury’.  		 			W Liu 		,  		 			X Zhang 		,  		 			P Liu 		,  		 			X Shen 		,  		 			T Lan 		,  		 			W Li 		,  		 			Q Jiang 		,  		 			X Xie 		,  		 			\& H Huang 		.  	 	 		\textit{Eur. J. Pharmacol}  		2010. 638 p. .  	 
\bibitem[Ohashi et al.]{b76}\label{b76} 	 		\textit{Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice},  		 			K Ohashi 		,  		 			H Iwatani 		,  		 			S Kihara 		.  		 	 
\bibitem[Gil-Bernabe et al. ()]{b83}\label{b83} 	 		‘Exogenous activated protein C inhibits the progression of diabetic nephropathy’.  		 			P Gil-Bernabe 		,  		 			C N D'alessandro-Gabazza 		,  		 			M Toda 		,  		 			D Boveda 		,  		 			Ruiz 		.  	 	 		\textit{J Thromb Haemost}  		2012. 10  (3)  p. .  	 
\bibitem[Tanji et al. ()]{b15}\label{b15} 	 		‘Expression of advanced glycation endproduces and their cellular receptor RAGE in diabetic nephropathy and non-diabetic renal disease’.  		 			N Tanji 		,  		 			G S Markowitz 		,  		 			C Fu 		,  		 			T Kislinger 		,  		 			A Taguchi 		,  		 			M Pischetsrieder 		,  		 			D Stern 		,  		 			A M Schmidt 		,  		 			V D D'agati 		.  	 	 		\textit{J Am Soc Nephrol}  		2000. 11 p. .  	 
\bibitem[Song et al. ()]{b27}\label{b27} 	 		‘Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation’.  		 			Y Song 		,  		 			C Li 		,  		 			L Cai 		.  	 	 		\textit{Exp. Mol. Patholo}  		2004. 76 p. .  	 
\bibitem[Tsuchiya et al. ()]{b87}\label{b87} 	 		‘FoxOs intergrate pleiotropic actions of insulin in vascular endothelium protect mice from atherosclerosis’.  		 			K Tsuchiya 		,  		 			J Tanaka 		,  		 			Y Shuiqing 		,  		 			C L Welch 		,  		 			R A Depinho 		.  	 	 		\textit{Cell Metab}  		2012. 15 p. .  	 
\bibitem[Schrijvers et al. ()]{b40}\label{b40} 	 		‘From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines’.  		 			B F Schrijvers 		,  		 			A S De Vriese 		,  		 			A Flyvbjerg 		.  	 	 		\textit{Endocr Rev}  		2004. 25  (6)  p. .  	 
\bibitem[Mima et al. ()]{b90}\label{b90} 	 		‘Glomerular-specific protein kinase C-?-induced insulin receptor substrate-1 dysfunction and insulin resistance in rat models of diabetes and obesity’.  		 			Y Mima 		,  		 			M Ohshiro 		,  		 			M Kitada 		,  		 			Matsumoto 		.  	 	 		\textit{Kidney international}  		2011. 79  (8)  p. .  	 
\bibitem[Zhang et al. ()]{b53}\label{b53} 	 		‘High glucose induces renal mesangial cell proliferation and fibronectin expression through JNK/NF-?B/NADPH oxidase/ROS pathway, which is inhibited by resveratrol’.  		 			L Zhang 		,  		 			S Pang 		,  		 			B Deng 		,  		 			L Qian 		,  		 			J Chen 		,  		 			J Zou 		,  		 			J Zheng 		,  		 			L 		,  		 			Yang 		,  		 			C Zhang 		,  		 			X Chen 		,  		 			Z Liu 		,  		 			Y Le 		.  	 	 		\textit{Int J Biochem Cell Biol}  		2012. 44 p. .  	 
\bibitem[Welsh et al. ()]{b91}\label{b91} 	 		‘Insulin signaling to the glomerular podocytes is critical for normal kidney function’.  		 			G I Welsh 		,  		 			L G Hale 		,  		 			V Eremina 		,  		 			M Jeansson 		,  		 			Y Maezawa 		.  	 	 		\textit{Cell metab}  		2010. 12 p. .  	 
\bibitem[Hermann et al. ()]{b88}\label{b88} 	 		‘Insulin-mediated stimulation of protein kinase Akt: A potent survival signaling cascade for endothelial cells’.  		 			C Hermann 		,  		 			B Assmus 		,  		 			C Urbich 		,  		 			A M Zeiher 		,  		 			S Dimmeler 		.  	 	 		\textit{Arterioscler. Thromb. Vasc. Biol}  		2000. 20 p. .  	 
\bibitem[International Diabetes Federation. IDF Diabetes Atlas Update Poster ()]{b1}\label{b1} 	 		\textit{International Diabetes Federation. IDF Diabetes Atlas Update Poster},  				 (Brussels, Belgium)  		2014.  	 	 (6th ed.; International Diabetes Federation) 
\bibitem[Mohamed et al. ()]{b68}\label{b68} 	 		‘Kidney proximal tubular epithelial-specific overexpression of netrin-1 suppression of COX-2-mediated PGE2 production in streptozotocin-induced diabetic mice’.  		 			R Mohamed 		,  		 			C Jayakumar 		,  		 			P V Ranganathan 		,  		 			V Ganapahty 		,  		 			G Ramesh 		.  	 	 		\textit{Am J Pathol}  		2012. 181 p. .  	 
\bibitem[Park et al. ()]{b58}\label{b58} 	 		‘Long-term dietary antioxidant cocktail supplementation effectively reduces renal inflammation in diabetic mice’.  		 			N Y Park 		,  		 			S K Park 		,  		 			\& Y Lim 		.  	 	 		\textit{Br. J. Nutr}  		2011. 106  (10)  p. .  	 
\bibitem[Fang and Sweeney ()]{b74}\label{b74} 	 		‘Mechanisms regulating energy metabolism by adiponectin in obesity and diabetes’.  		 			X Fang 		,  		 			\& G Sweeney 		.  	 	 		\textit{Biochemical Society Transactions}  		2006. 34  (5)  p. .  	 
\bibitem[Napetschnig and Wu ()]{b36}\label{b36} 	 		‘Molecular basis of NF-?B signaling’.  		 			J Napetschnig 		,  		 			\& H Wu 		.  	 	 		\textit{Annu Rev Biophys}  		2013. 42 p. .  	 
\bibitem[Arora and Singh ()]{b9}\label{b9} 	 		‘Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update’.  		 			M K Arora 		,  		 			U K Singh 		.  	 	 		\textit{Vascular Pharmacology}  		2013. 58 p. .  	 
\bibitem[Sheridan ()]{b2}\label{b2} 	 		‘Molecular mechanisms underlying diabetic nephropathy’.  		 			A M Sheridan 		.  	 	 		\textit{Nephrology Rounds}  		2006. 4  (8) .  	 
\bibitem[Susztak et al. ()]{b49}\label{b49} 	 		‘Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease’.  		 			K Susztak 		,  		 			E Böttinger 		,  		 			A Novetsky 		,  		 			D Liang 		,  		 			Y Zhu 		,  		 			E Ciccone 		,  		 			D Wu 		,  		 			S Dunn 		,  		 			P Mccue 		,  		 			K Sharma 		.  	 	 		\textit{Diabetes}  		2004. 53 p. .  	 
\bibitem[Sedeek et al. ()]{b59}\label{b59} 	 		‘NADPH Oxidases, reactive oxygen species, and the kidney: Friend and Foe’.  		 			M Sedeek 		,  		 			Nasrallah 		,  		 			\& Rl Touyz 		,  		 			Hebert 		.  	 	 		\textit{J Am Nephrol}  		2013. 24 p. .  	 
\bibitem[Ww et al. ()]{b64}\label{b64} 	 		‘Netrin-1 and kidney injury. 1. Netrin-1 protects against ischemia-reperfusion injury of the kidney’.  		 			Ww 		,  		 			W B Wang 		,  		 			\& G Reeves 		,  		 			Ramesh 		.  	 	 		\textit{Am J Physiol Renal Physiol}  		2008. 294  (4)  p. .  	 
\bibitem[Mezzano et al. ()]{b37}\label{b37} 	 		‘NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy’.  		 			S Mezzano 		,  		 			C Aros 		,  		 			A Droguett 		,  		 			M E Burgos 		,  		 			L Ardiles 		,  		 			C Flores 		,  		 			H Schneider 		,  		 			M Ruiz-Ortega 		,  		 			\& J Egido 		.  	 	 		\textit{Nephrol. Dial. Transplant}  		2004. 19  (10)  p. .  	 
\bibitem[Heuer & M and Breyer ()]{b47}\label{b47} 	 		\textit{Osteopontin in diabetic nephropathy: signpost or road? Kideny international},  		 			J G D Heuer \& M 		,  		 			Breyer 		.  		2010. 77 p. .  	 
\bibitem[Sodhi et al. ()]{b52}\label{b52} 	 		‘Osteopontin mediates hypoxia-induced proliferation of cultured mesangial cells: role of PKC and p38 MAPK’.  		 			C P Sodhi 		,  		 			D Battle 		,  		 			A Sahai 		.  	 	 		\textit{Kidney int}  		2000. 58 p. .  	 
\bibitem[Scatena et al. ()]{b46}\label{b46} 	 		‘Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease’.  		 			M Scatena 		,  		 			L Liaw 		,  		 			C M Giachelli 		.  	 	 		\textit{Arterioscler Thromb Vasc Biol}  		2007. 27 p. .  	 
\bibitem[Forbes et al. ()]{b54}\label{b54} 	 		‘Oxidative stress as a major culprit in kidney disease in diabetes’.  		 			J M Forbes 		,  		 			M T Coughlan 		,  		 			M E Cooper 		.  	 	 		\textit{Diabetes}  		2008. 57  (6)  p. .  	 
\bibitem[Kashihara et al. ()]{b56}\label{b56} 	 		‘Oxidative stress in diabetic nephropathy’.  		 			N Kashihara 		,  		 			Y Haruna 		,  		 			V K Kondeti 		,  		 			Y S Kanwar 		.  	 	 		\textit{Curr. Med. Chem}  		2010. 17 p. .  	 
\bibitem[Grenz et al. ()]{b65}\label{b65} 	 		‘Partial netrin-1 deficiency aggravates acute kidney injury’.  		 			A Grenz 		,  		 			J H Dalton 		,  		 			J D Bauerle 		,  		 			A Badulak 		,  		 			D Ridyard 		.  	 	 		\textit{PloS One}  		2011. 6  (5)  p. e14812.  	 
\bibitem[Arya et al. ()]{b3}\label{b3} 	 		‘Pathogenesis of diabetic nephropathy’.  		 			A Arya 		,  		 			S Aggarwal 		,  		 			H N Yadav 		.  	 	 		\textit{Int J Pharm Pharm Sci}  		2010. 2  (4)  p. .  	 
\bibitem[Adler et al. ()]{b35}\label{b35} 	 		‘Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria’.  		 			S G Adler 		,  		 			S Schwartz 		,  		 			M E Williams 		,  		 			C Arauz-Pacheco 		,  		 			W K Bolton 		.  	 	 		\textit{Clin. J. Am. Soc. Nephrol}  		2010. 5  (8)  p. .  	 
\bibitem[Xie et al. ()]{b44}\label{b44} 	 		‘Polydatin ameliorates experimental diabetes-induced fibronectin through inhibiting the activation of NF-?B signaling pathway in rat glomerular mesangial cells’.  		 			X Xie 		,  		 			J Peng 		,  		 			K Huang 		,  		 			J Huang 		,  		 			X Y Shen 		,  		 			P Liu 		,  		 			H Huang 		.  	 	 		\textit{Mol Cell Endocrinol}  		2012. 362 p. .  	 
\bibitem[Tak et al. ()]{b69}\label{b69} 	 		‘Protective role for netrin-1 during diabetic nephropathy’.  		 			E Tak 		,  		 			D Ridyard 		,  		 			A Badulak 		,  		 			A Giebler 		,  		 			U Shabeka 		,  		 			T Werner 		.  	 	 		\textit{J Mol Med}  		2013. 91 p. .  	 
\bibitem[Nishizuka ()]{b23}\label{b23} 	 		‘Protein kinase C and lipid signaling for sustained cellular responses’.  		 			Y Nishizuka 		.  	 	 		\textit{FASEB J}  		1995. 9 p. .  	 
\bibitem[Bondeva and Wolf ()]{b60}\label{b60} 	 		‘Reactive oxygen species in diabetic nephropathy: friend or foe?’.  		 			T Bondeva 		,  		 			\& G Wolf 		.  	 	 		\textit{Nephrol. Dial. Transplant}  		2014. 29  (11)  p. .  	 
\bibitem[Balakumar et al. ()]{b8}\label{b8} 	 		‘Recent Advances in Pharmacotherapy for Diabetic Nephropathy: Current Perspectives and Future Directions’.  		 			P Balakumar 		,  		 			M K Arora 		,  		 			S S Ganti 		,  		 			J Reddy 		,  		 			M Singh 		.  	 	 		\textit{Pharmacological Research}  		2009. 60 p. .  	 
\bibitem[Yokoi et al. ()]{b34}\label{b34} 	 		‘Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis’.  		 			H Yokoi 		,  		 			M Mukoyama 		,  		 			T Nagae 		,  		 			K Mori 		,  		 			T Suganami 		,  		 			K Sawai 		,  		 			T Yoshioka 		,  		 			M Koshikawa 		,  		 			T Nishida 		,  		 			M Takigawa 		,  		 			A Sugawara 		,  		 			K Nakao 		.  	 	 		\textit{J. Am. Soc. Nephrol}  		2004. 15 p. .  	 
\bibitem[Perkins et al. ()]{b61}\label{b61} 	 		‘Regression of microalbuminuria in type 1 diabetes’.  		 			B A Perkins 		,  		 			L H Ficociello 		,  		 			K H Silva 		.  	 	 		\textit{N Engl J Med}  		2003. 348 p. .  	 
\bibitem[Kuboki et al. ()]{b85}\label{b85} 	 		‘Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: A specific vascular action of insulin’.  		 			K Kuboki 		,  		 			Z Y Jiang 		,  		 			N Takahara 		,  		 			S W Ha 		.  	 	 		\textit{Circulation}  		2000. 101 p. .  	 
\bibitem[Suzuki et al. ()]{b16}\label{b16} 	 		‘Relationship between the expression of advanced glycation end-products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy’.  		 			D Suzuki 		,  		 			M Toyoda 		,  		 			N Yamamoto 		,  		 			M Miyauchi 		,  		 			M Katoh 		,  		 			M Kimura 		,  		 			M Maruyama 		,  		 			M Honma 		,  		 			T Umezono 		,  		 			M Yagame 		.  	 	 		\textit{Intern Med}  		2006. 45 p. .  	 
\bibitem[Nagarajan et al. ()]{b42}\label{b42} 	 		‘Repression of transforming-growth-factor-beta-mediated transcription by nuclear factor kappaB’.  		 			R P Nagarajan 		,  		 			F Chen 		,  		 			W Li 		,  		 			E Vig 		,  		 			M A Harrington 		,  		 			H Nakshatri 		,  		 			Y Chen 		.  	 	 		\textit{Biochem J}  		2000. 348 p. .  	 
\bibitem[Ha et al. ()]{b39}\label{b39} 	 		‘Role of high glucose-induced nuclear factor-kappa B activation in monocyte chemoattractant protein-1 expression by mesangial cells’.  		 			H Ha 		,  		 			M R Yu 		,  		 			Y J Choi 		,  		 			M Kitamura 		,  		 			H B Lee 		.  	 	 		\textit{J. Am. Soc. Nephrol}  		2002. 13 p. .  	 
\bibitem[Ramesh ()]{b66}\label{b66} 	 		\textit{Role of netrin-1 beyone the brain: from biomarker of tissue injury to therapy for inflammatory disease},  		 			G Ramesh 		.  		2012. 2 p. .  	 	 (Recent pat biomark) 
\bibitem[Ha et al. ()]{b0}\label{b0} 	 		‘Role of reactive oxygen species in the pathogenesis of diabetic nephropathy’.  		 			H Ha 		,  		 			I A Hwang 		,  		 			J H Park 		,  		 			H B Lee 		.  	 	 		\textit{Diabetes Research and Clinical Practice}  		2008. 82 p. .  	 
\bibitem[Jeong et al. ()]{b57}\label{b57} 	 		‘Schizandrin prevents damage of murine mesangial cells via blocking NADPH oxidase-induced ROS signaling in high glucose’.  		 			S Jeong 		,  		 			S J Kim 		,  		 			T H Kwon 		,  		 			K Y Yu 		,  		 			S Y Kim 		.  	 	 		\textit{Food and Chemical Toxicology}  		2012. 50 p. .  	 
\bibitem[Okado et al. ()]{b41}\label{b41} 	 		‘Smad7 mediates transforming growth factor-beta-induced apoptosis in mesangial cells’.  		 			T Okado 		,  		 			Y Terada 		,  		 			H Tanaka 		,  		 			S Inoshita 		,  		 			A Nakao 		,  		 			S Sasaki 		.  	 	 		\textit{Kidney int}  		2002. 62 p. .  	 
\bibitem[Su et al.]{b70}\label{b70} 	 		 			Y X Su 		,  		 			H C Deng 		,  		 			M X Zhang 		,  		 			J Long 		,  		 			Z G Peng 		.  		\textit{Adiponectin inhibits PDGF-induced},  				 	 
\bibitem[Forbes et al. ()]{b21}\label{b21} 	 		‘The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes’.  		 			J M Forbes 		,  		 			V Thallas 		,  		 			M C Thomas 		,  		 			H W Founds 		,  		 			W C Burns 		,  		 			G Jerums 		,  		 			M E Cooper 		.  	 	 		\textit{Faseb J}  		2003. 17  (12)  p. .  	 
\bibitem[Tuttle et al. ()]{b26}\label{b26} 	 		‘The effect of ruboxistaurin on nephropathy in type 2 diabetes’.  		 			K R Tuttle 		,  		 			G L Bakris 		,  		 			R D Toto 		,  		 			J B Mcgill 		,  		 			K Hu 		,  		 			P W Anderson 		.  	 	 		\textit{Diabetes Care}  		2005. 28 p. .  	 
\bibitem[Tessier-Lavigne and Goodman ()]{b62}\label{b62} 	 		‘The molecular biology of axon guidance’.  		 			M Tessier-Lavigne 		,  		 			C S Goodman 		.  	 	 		\textit{Science}  		1996. 274 p. .  	 
\bibitem[Navankasattusas et al. ()]{b63}\label{b63} 	 		‘The netrin receptor UNC5B promotes angiogenesis in specific vascular beds’.  		 			S Navankasattusas 		,  		 			K J Whitehead 		,  		 			A Suli 		,  		 			L K Sorensen 		,  		 			A H Lim 		,  		 			J Zhao 		.  	 	 		\textit{Development}  		2008. 135 p. .  	 
\bibitem[Yan et al. ()]{b22}\label{b22} 	 		‘The RAGE axis: a Fundamental mechanism signaling danger to the vulnerable vasculature’.  		 			S F Yan 		,  		 			R Ramasamy 		,  		 			A M Schemidt 		.  	 	 		\textit{Circ. Res}  		2010. 106 p. .  	 
\bibitem[Lorenzen et al. ()]{b50}\label{b50} 	 		‘The role of osteopontin in the development of albuminuria’.  		 			J Lorenzen 		,  		 			R Shah 		,  		 			A Biser 		,  		 			S A Staicu 		,  		 			T Niranjan 		,  		 			A M Garcia 		,  		 			A Gruenwald 		,  		 			D B Thomas 		,  		 			I F Shatat 		,  		 			K Supe 		,  		 			R P Woroniecki 		,  		 			K Susztak 		.  	 	 		\textit{J Am Soc Nephrol}  		2008. 19 p. .  	 
\bibitem[Hills and Squires ()]{b12}\label{b12} 	 		‘The role of TGF-? and epithelial-to mesenchymal transition in diabetic nephropathy’.  		 			C E Hills 		,  		 			P E Squires 		.  	 	 		\textit{Cytokine \& Growth Reviews}  		2011. 22 p. .  	 
\bibitem[Magri and Fava ()]{b11}\label{b11} 	 		‘The role of tubular injury in diabetic nephropathy’.  		 			C J Magri 		,  		 			S Fava 		.  	 	 		\textit{European Journal of Internal Medicine}  		2009. 20 p. .  	 
\bibitem[Qi et al. ()]{b28}\label{b28} 	 		‘Transforming growth factor-?/connective tissue growth factor axis in the kidney’.  		 			W Qi 		,  		 			X M Chen 		,  		 			P Poronnik 		,  		 			C A Pollock 		.  	 	 		\textit{The International Journal of Biochemistry \& Cell Biology}  		2008. 40 p. .  	 
\bibitem[Zozulinska & B. Wierusz-Wysocka ()]{b67}\label{b67} 	 		‘Type 2 diabetes mellitus as inflammatory disease’.  		 			D Zozulinska \& B. Wierusz-Wysocka 		.  	 	 		\textit{Diabetes Research and Clinical Practice}  		2006. 74 p. .  	 
\bibitem[Rask-Madsen and King ()]{b10}\label{b10} 	 		‘Vascular Complications of Diabetes: Mechanisms of injury and protective factors’.  		 			C Rask-Madsen 		,  		 			. \& G L King 		.  	 	 		\textit{Cell Metabolism}  		2013. 17 p. .  	 
\end{bibitemlist}
 			 		 	 
\end{document}
